These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 7403181)
1. Drug and other hazards to the fetus and newborn. Freeman MM; Finkel MJ Prog Clin Biol Res; 1980; 36():67-72. PubMed ID: 7403181 [No Abstract] [Full Text] [Related]
2. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration. Kelsey FO Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617 [No Abstract] [Full Text] [Related]
3. [On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation]. Maio G Dtsch Med Wochenschr; 2001 Oct; 126(42):1183-6. PubMed ID: 11607860 [No Abstract] [Full Text] [Related]
5. Methods of evaluating the alleged teratogenicity of environmental agents. Brent RL Prog Clin Biol Res; 1985; 163C():191-5. PubMed ID: 3991621 [No Abstract] [Full Text] [Related]
6. Research regulation, and development of new pharmaceuticals: past, present, and future. 1. Lasagna L Am J Med Sci; 1972 Jan; 263(1):9-18. PubMed ID: 4257990 [No Abstract] [Full Text] [Related]
7. Systematic identification of drugs that cause birth defects--a new opportunity. Mitchell AA N Engl J Med; 2003 Dec; 349(26):2556-9. PubMed ID: 14695418 [No Abstract] [Full Text] [Related]
8. Pregnancy and the drug dilemma. Meadows M FDA Consum; 2001; 35(3):16-20. PubMed ID: 11458544 [No Abstract] [Full Text] [Related]
9. Accutane risk management program strengthened. FDA Consum; 2002; 36(1):8. PubMed ID: 11881607 [No Abstract] [Full Text] [Related]
10. Acne drug controversy ignites turf battle over prescribing. Thomas P Med World News; 1988 Jun; 29(11):46-7. PubMed ID: 10313737 [No Abstract] [Full Text] [Related]
11. FDA problems with medications in the marketplace: IV. Drugs and the unborn. Archambault GF Hosp Formul; 1977 Jan; 12(1):56. PubMed ID: 10236016 [No Abstract] [Full Text] [Related]
12. Regulatory aspects of teratology: role of the Food and Drug Administration. Kelsey FO Teratology; 1982 Apr; 25(2):193-9. PubMed ID: 7048616 [TBL] [Abstract][Full Text] [Related]
13. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin). Doshi A Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569 [No Abstract] [Full Text] [Related]
14. A pox on your practice. iPLEDGE program scars dermatologists. Ortolon K Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578 [No Abstract] [Full Text] [Related]
15. An innovative approach to determine fetal risk: the FDA Office of Women's Health pregnancy exposure registry web listing. Sharma P; Parekh A; Uhl K Womens Health Issues; 2008; 18(4):226-8. PubMed ID: 18468921 [No Abstract] [Full Text] [Related]
16. Potential subversion of pregnancy prevention program in the managed care setting. Wilkin JK Arch Dermatol; 1997 Feb; 133(2):243-4. PubMed ID: 9041846 [No Abstract] [Full Text] [Related]
17. [Pharmacological principles in pregnancy]. Villanueva LA; Valenzuela F Gac Med Mex; 1998; 134(5):575-82. PubMed ID: 9842139 [TBL] [Abstract][Full Text] [Related]
18. Improper interpretation of data concerning teratogenicity: a case report. Staples RE Prog Clin Biol Res; 1985; 163C():161-3. PubMed ID: 3921981 [No Abstract] [Full Text] [Related]
19. Drug therapy and the developing human: who cares? Mirkin BL Clin Res; 1975 Apr; 23(3):106-13. PubMed ID: 10237294 [No Abstract] [Full Text] [Related]
20. Pregnancy and pills. New research finds prescriptions may be safer than you think. Schultz S US News World Rep; 1999 Apr; 126(13):64-6. PubMed ID: 10351523 [No Abstract] [Full Text] [Related] [Next] [New Search]